Device: Desktop
Bootstrap:

NEWS CENTER

Press Releases

01/27/2020 - PR: Vyera Responds to U.S. Federal Trade Commission Civil Action Related to Daraprim®

12/17/2019 - PR: CytoDyn Signs Definitive Agreements with Vyera Pharmaceuticals to Commercialize Leronlimab in the U.S. for the Treatment of HIV

11/15/2018 - PR: Vyera Pharmaceuticals Receives FDA Clearance To Initiate A Phase 1 Study Of A New Chemical Entity Designed As A Potential Treatment For Toxoplasmosis.

02/08/2018 - PR: Vyera Pharmaceuticals has initiated a Phase 1 study of a new dihydrofolate reductase inhibitor designed as a potential treatment for toxoplasmosis.

Publications

1/28/2019 - Hopper AT, Brockman A, Wise A, et al. Discovery of selective Toxoplasma gondii dihydrofolate reductase inhibitors for the treatment of toxoplasmosis. J Med Chem. 2019. DOI: https://pubs.acs.org/doi/pdfplus/10.1021/acs.jmedchem.8b01754. Accessed 28 Jan 2019.

You are about to enter a site that is for US healthcare professionals only. By clicking "Confirm" below, you certify that you are a healthcare professional and that you wish to proceed to the Healthcare Professionals Only section of this site. Products or treatments described on this site are available in the US but may not be available in other countries.

I am a licensed healthcare professional and wish to proceed to the Healthcare Professionals section of this site.